Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
supplementary figures from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
View through CrossRef
<p>Figure S1A. Kaplan-Meier plot of survival by CXCL11 group for gp100-treated melanoma patients Figure S1B. Kaplan-Meier plot of survival by CXCL11 group for ipilimumab-treated melanoma patients Figure S1C. Kaplan-Meier plot of survival by MICA group for gp100-treated melanoma patients Figure S1D. Kaplan-Meier plot of survival by MICA group for ipilimumab-treated melanoma patients Figure S1E. Kaplan-Meier plot of survival by VEGF group for gp100-treated melanoma patients Figure S1F. Kaplan-Meier plot of survival by VEGF group for ipilimumab-treated melanoma patients Figure S2A. Kaplan-Meier plot of survival by CXCL11, Compassionate use study Figure S2B. Kaplan-Meier plot of survival by MICA, Compassionate use study Figure S2C. Kaplan-Meier plot of survival by VEGF, Compassionate use study</p>
American Association for Cancer Research (AACR)
Title: supplementary figures from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Description:
<p>Figure S1A.
Kaplan-Meier plot of survival by CXCL11 group for gp100-treated melanoma patients Figure S1B.
Kaplan-Meier plot of survival by CXCL11 group for ipilimumab-treated melanoma patients Figure S1C.
Kaplan-Meier plot of survival by MICA group for gp100-treated melanoma patients Figure S1D.
Kaplan-Meier plot of survival by MICA group for ipilimumab-treated melanoma patients Figure S1E.
Kaplan-Meier plot of survival by VEGF group for gp100-treated melanoma patients Figure S1F.
Kaplan-Meier plot of survival by VEGF group for ipilimumab-treated melanoma patients Figure S2A.
Kaplan-Meier plot of survival by CXCL11, Compassionate use study Figure S2B.
Kaplan-Meier plot of survival by MICA, Compassionate use study Figure S2C.
Kaplan-Meier plot of survival by VEGF, Compassionate use study</p>.
Related Results
Data from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Data from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
<div>Abstract<p>Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumo...
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Abstract
Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumor...
Data from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Data from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
<div>Abstract<p>Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumo...
supplementary figures from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
supplementary figures from Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
<p>Figure S1A. Kaplan-Meier plot of survival by CXCL11 group for gp100-treated melanoma patients Figure S1B. Kaplan-Meier plot of survival by CXCL11 group for ipilimumab-trea...
Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials
Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials
Nivolumab, a completely human programmed death-1 inhibitor antibody, was first approved by the Food and Drug Administration for patients with advanced malignant melanoma resistant ...
Construction of competing endogenous RNA interaction networks as prognostic markers in metastatic melanoma
Construction of competing endogenous RNA interaction networks as prognostic markers in metastatic melanoma
AbstractMalignant melanoma (MM) is a highly aggressive, metastatic cancer originating from melanocytes. These tumors have an extremely poor prognosis. MM accounts for 4% of skin ca...
Abstract PL02-03: Immune modulation for cancer therapy: Assessing antagonists and agonists
Abstract PL02-03: Immune modulation for cancer therapy: Assessing antagonists and agonists
Abstract
The past decade has been a period of tremendous progress in the area of cancer immunotherapy. The field has progressed from a point where very modest subset...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...